Relay Therapeutics Inc Share Price Today: Live Updates & Key Insights

Relay Therapeutics Inc share price today is $9.93, up -0.9%. The stock opened at $10.33 against the previous close of $10, with an intraday high of $10.71 and low of $9.7.

Relay Therapeutics Inc Share Price Chart

Relay Therapeutics Inc

us-stock
To Invest in {{usstockname}}
us-stock

Relay Therapeutics Inc Share Price Performance

$9.93 -0.009(-0.9%) RLAY at 23 Mar 2026 03:02 PM Biotechnology
Lowest Today 9.7
Highest Today 10.71
Today’s Open 10.33
Prev. Close 10
52 Week High 11.49
52 Week Low 1.78
Day’s Range: Low 9.7 High 10.71
52-Week Range: Low 1.78 High 11.49
1 day return -
1 Week return -2.27
1 month return +10.86
3 month return +14.91
6 month return +118.54
1 year return +220.38
3 year return -35.08
5 year return -74.71
10 year return -

Relay Therapeutics Inc Institutional Holdings

SB INVESTMENT ADVISERS (UK) LTD 15.61

COMMODORE CAPITAL LP 9.51

Point72 Asset Management, L.P. 8.27

BlackRock Inc 7.70

Casdin Capital, LLC 7.28

Vanguard Group Inc 5.42

Bellevue Group AG 4.67

TANG CAPITAL MANAGEMENT LLC 4.51

Vanguard Total Stock Mkt Idx Inv 2.88

State Street Corp 2.83

Nextech Invest, Ltd. 2.63

iShares Russell 2000 ETF 1.92

Geode Capital Management, LLC 1.91

State Street® SPDR® S&P® Biotech ETF 1.80

Spruce Street Capital LP 1.67

Dimensional Fund Advisors, Inc. 1.39

MPM Oncology Impact Management LP 1.28

Balyasny Asset Management LLC 1.17

The Goldman Sachs Group Inc 1.05

TCG Crossover Management, LLC 1.01

Morgan Stanley - Brokerage Accounts 0.99

Alphabet Inc 0.88

Two Sigma Investments LLC 0.87

Vanguard Institutional Extnd Mkt Idx Tr 0.80

Fidelity Small Cap Index 0.77

iShares Russell 2000 Value ETF 0.68

T. Rowe Price Health Sciences 0.57

iShares Biotechnology ETF 0.54

State St Russell Sm/Mid Cp® Indx SL Cl I 0.46

Vanguard Russell 2000 ETF 0.38

Fidelity Extended Market Index 0.37

BlackRock Advantage Small Cap Core Instl 0.37

Schwab US Small-Cap ETF™ 0.36

DFA US Small Cap I 0.35

Vanguard Strategic Small-Cap Equity Inv 0.31

Allianz Thematica P EUR 0.31

DFA US Micro Cap I 0.26

State St Russell Sm Cap® Indx SL Cl I 0.26

Rhenman Healthcare Equity L/S RC2 SEK 0.26

Dimensional US Small Cap ETF 0.25

Relay Therapeutics Inc Market Status

Strong Buy: 6

Buy: 5

Hold: 2

Sell: 0

Strong Sell: 0

Relay Therapeutics Inc Fundamentals

Market Cap 1771.17 M

PB Ratio 3.1518

PE Ratio 0.0

Enterprise Value 1265.20 M

Total Assets 621.33 M

Volume 3824089

Relay Therapeutics Inc Company Financials

Annual Revenue FY24:10007000 10.0M, FY23:25800000 25.8M, FY22:1381000 1.4M, FY21:3029000 3.0M, FY20:82654000 82.7M

Annual Profit FY24:10007000 10.0M, FY23:null 0.0M, FY22:1381000 1.4M, FY21:3029000 3.0M, FY20:82654000 82.7M

Annual Net worth FY24:-337708000 -337.7M, FY23:-325981000 -326.0M, FY22:-254259000 -254.3M, FY21:-496808000 -496.8M, FY20:-49012000 -49.0M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:677000 0.7M, Q1/2025:7679000 7.7M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:-748000 -0.7M, Q2/2025:677000 0.7M, Q1/2025:7679000 7.7M, Q3/2024:null 0.0M, Q2/2024:-1368000 -1.4M

Quarterly Net worth Q3/2025:-74149000 -74.1M, Q2/2025:-70375000 -70.4M, Q1/2025:-77065000 -77.1M, Q3/2024:-88105000 -88.1M, Q2/2024:-92212000 -92.2M

About Relay Therapeutics Inc & investment objective

Company Information Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and aGal chaperone for Fabry diseases. It also develops RLY-8161, an oncogene driver that belongs to the RAS family of signaling proteins. In addition, the company develops lirafugratinib (RLY-4008), a receptor tyrosine kinase for the treatment of cancer. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; Elevar Therapeutics, Inc. for the development and commercialization of RLY-4008; and Pfizer Inc. for the development of RLY-2608 in combination with fulvestrant and atirmociclib. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Organisation Biotechnology

Employees 192

Industry Biotechnology

CEO Dr. Sanjiv K. Patel M.A., M.B.A., M.D., MBBS

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Relay Therapeutics Inc FAQs

What is the share price of Relay Therapeutics Inc today?

The current share price of Relay Therapeutics Inc is $9.93.

Can I buy Relay Therapeutics Inc shares in India?

Yes, Indian investors can buy Relay Therapeutics Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy Relay Therapeutics Inc shares in India?

You can easily invest in Relay Therapeutics Inc shares from India by:

Can I buy fractional shares of Relay Therapeutics Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Relay Therapeutics Inc?

Relay Therapeutics Inc has a market cap of $1771.17 M.

In which sector does Relay Therapeutics Inc belong?

Relay Therapeutics Inc operates in the Biotechnology sector.

What documents are required to invest in Relay Therapeutics Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of Relay Therapeutics Inc?

The PE ratio of Relay Therapeutics Inc is N/A and the PB ratio is 3.15.